Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial.
Saved in:
| Title: | Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled Trial. |
|---|---|
| Authors: | Connor MJ; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. Electronic address: m.connor@imperial.ac.uk., Shah TT; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK., Sukumar J; Imperial Clinical Trials Unit (ICTU), School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Basak D; Department of Oncology, Imperial College Healthcare NHS Foundation Trust, Charing Cross Hospital, London, UK., Fiorentino F; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK., Heath C; Department of Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Horan G; Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust & The Cancer Centre, Addenbrooke's Hospital, Cambridge, UK., Johnson N; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK., Khoo V; Department of Oncology, The Royal Marsden Hospital, London, UK., Khoubehi B; Department of Urology, Chelsea & Westminster NHS Foundation Trust, London, UK., Klimowska-Nassar N; Imperial Clinical Trials Unit (ICTU), School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Mangar S; Department of Oncology, Imperial College Healthcare NHS Foundation Trust, Charing Cross Hospital, London, UK., McGrath J; Department of Urology, Royal Devon and Exeter NHS Foundation Trust, Oncology, Exeter, UK., Nohpal de la Rosa C; Imperial Clinical Trials Unit (ICTU), School of Public Health, Faculty of Medicine, Imperial College London, London, UK., Price D; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK., Rai B; Department of Urology, Newcastle Freeman Hospital, Newcastle, UK., Sarwar N; Department of Oncology, Imperial College Healthcare NHS Foundation Trust, Charing Cross Hospital, London, UK., Smith A; Department of Histopathology, Imperial College Healthcare NHS Foundation Trust, Charing Cross Hospital, London, UK., Staffurth JN; Department of Oncology and Radiotherapy, Cardiff University, Cardiff, UK., Tam H; Department of Radiology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK., Thippu Jayaprakash K; Department of Oncology, The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust & The Cancer Centre, Addenbrooke's Hospital, Cambridge, UK., Winkler M; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK., Dudderidge T; Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Ahmed HU; Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK. |
| Corporate Authors: | IP2-ATLANTA Trial Investigators |
| Source: | European urology oncology [Eur Urol Oncol] 2026 Apr; Vol. 9 (2), pp. 276-285. Date of Electronic Publication: 2025 Jun 13. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
